

ProtoKinetix, Inc.  
Form SC 13D/A  
December 07, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D/A  
(Amendment No. 6)\*

Under the Securities Exchange Act of 1934

PROTOKINETIX, INCORPORATED  
(Name of Issuer)

Common Stock, par value \$0.0000053 per share  
(Title of Class of Securities)

743722100  
(CUSIP Number)

Clarence E. Smith  
1845 County Road #214  
St. Augustine, Florida 32084  
304-299-5070  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

November 30, 2016  
(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

---

CUSIP No. 743722100

NAMES OF REPORTING  
PERSONS

1

Clarence E. Smith

CHECK THE APPROPRIATE BOX (a)  
IF A MEMBER OF A GROUP (b)

2

SEC USE ONLY

3

SOURCE OF FUNDS (SEE  
INSTRUCTIONS)

4

PF

CHECK BOX IF DISCLOSURE OF  
LEGAL PROCEEDINGS IS  
REQUIRED PURSUANT TO ITEM  
2(D) OR 2(E)

5

CITIZENSHIP OR PLACE OF  
ORGANIZATION

6

United States

SOLE VOTING POWER

<sup>7</sup> 58,820,626<sup>1</sup>

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON WITH

SHARED VOTING POWER

<sup>8</sup> N/A

SOLE DISPOSITIVE POWER

<sup>9</sup> 58,820,626

SHARED DISPOSITIVE POWER

<sup>10</sup> N/A

AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY  
EACH REPORTING PERSON

11

58,820,626

CHECK BOX IF THE  
AGGREGATE AMOUNT IN ROW  
(11) EXCLUDES CERTAIN  
SHARES (SEE INSTRUCTIONS)

12

13 PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW (11)

24.93%

14 TYPE OF REPORTING PERSON  
IN

---

<sup>1</sup> Includes 49,070,500 shares of common stock held by Mr. Smith personally; 2,900,126 shares held in Mr. Smith's trust; 1,850,000 held in Mr. Smith's retirement account; and vested options held by Mr. Smith for 5,000,000 shares of common stock.

---

This Amendment No. 6 to Schedule 13D, dated November 30, 2016 (this "Amendment No. 6"), is being filed by the undersigned to amend the Schedule 13D originally filed on March 24, 2014 (the "Original 13D"), Amendment No. 1 to the Original 13D originally filed on July 8, 2015 (the "Amendment No. 1"), Amendment No. 2 to the Original 13D originally filed on May 5, 2016 (the "Amendment No. 2"), Amendment No. 3 to the Original 13D originally filed on July 11, 2016 (the "Amendment No. 3"), Amendment No. 4 to the Original 13D originally filed on September 19, 2016 (the "Amendment No. 4") and Amendment No. 5 to the Original 13D originally filed on November 7, 2016 (the "Amendment No. 5"). This Amendment No. 6 relates to the common stock, \$0.0000053 par value, of ProtoKinetix, Incorporated ("ProtoKinetix"). This Amendment is being filed by Mr. Smith to report an increase in his beneficial ownership of common stock due to acquisitions by Mr. Smith of common stock of ProtoKinetix, including unintentionally omitted purchases of the Company's securities on the open market on October 12, 2016 and October 14, 2016. Except as set forth herein, the Original Schedule 13D is unmodified.

#### ITEM 1. SECURITY AND ISSUER

No change.

#### ITEM 2. IDENTITY AND BACKGROUND

No change.

#### ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

On October 12, 2016 and October 14, 2016, Mr. Smith's trust purchased a total of 105,900 shares of common stock of the Company on the open market at prices that ranged from \$0.053 to \$0.057 per share for a total amount of \$5,808.35.

On November 30, 2016, Mr. Smith purchased 3,500,000 shares at \$0.04 per share in a private placement for total proceeds of \$140,000 to the Company.

#### ITEM 4. PURPOSE OF THE TRANSACTION

No change.

#### ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) Mr. Smith beneficially owns 58,820,626 shares of common stock of ProtoKinetix which amounts to approximately 24.93% of the total number of common shares currently outstanding, of which 49,070,500 are owned directly by Mr. Smith, or held in a brokerage account for his benefit, 2,900,126 shares are owned indirectly by Mr. Smith through his trust, 1,850,000 are owned indirectly by Mr. Smith through his retirement account, and vested options to purchase 5,000,000 shares are owned directly by Mr. Smith.

(b) Mr. Smith has sole voting and dispositive power over 58,820,626 shares of common stock of ProtoKinetix.

(a) On October 12, 2016 and October 14, 2016, Mr. Smith's trust purchased a total of 105,900 shares of common stock of the Company on the open market at prices that ranged from \$0.053 to \$0.057 per share for a total amount of \$5,808.35.

(b) On November 30, 2016, Mr. Smith purchased 3,500,000 shares at \$0.04 per share in a private placement for gross proceeds of \$140,000 to the Company.

(c) No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock described herein, except as described in Item 6, below.

(d) Not applicable.

**ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE SECURITIES OF THE ISSUER.**

No change.

**ITEM 7. MATERIAL TO BE FILED AS EXHIBITS**

No change.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 7, 2016 By: /s/ Clarence E. Smith  
Clarence E. Smith